<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095693</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01457</org_study_id>
    <secondary_id>NCI-2012-01457</secondary_id>
    <secondary_id>OSU-0441</secondary_id>
    <secondary_id>CDR0000393968</secondary_id>
    <secondary_id>NCI-6608</secondary_id>
    <secondary_id>OSU-2004C0068</secondary_id>
    <secondary_id>OSU 0441</secondary_id>
    <secondary_id>6608</secondary_id>
    <secondary_id>N01CM62207</secondary_id>
    <secondary_id>P30CA016058</secondary_id>
    <secondary_id>N01CM62206</secondary_id>
    <secondary_id>U01CA076576</secondary_id>
    <nct_id>NCT00095693</nct_id>
  </id_info>
  <brief_title>Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer</brief_title>
  <official_title>Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have&#xD;
      locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may&#xD;
      stop the growth of tumor cells by blocking the enzymes necessary for their growth and by&#xD;
      stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine objective response rate in patients with locally advanced, metastatic, or&#xD;
      locally recurrent differentiated thyroid cancer treated with sorafenib (BAY 43-9006).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of this drug in these patients. II. Correlate thyroglobulin levels&#xD;
      with tumor response in patients treated with this drug.&#xD;
&#xD;
      III. Correlate fludeoxyglucose F 18 positron emission tomography results with tumor response&#xD;
      in patients treated with this drug.&#xD;
&#xD;
      IV. Correlate tumor permeability and vascularity, as determined by dynamic contrast-enhanced&#xD;
      MRI, with tumor response in patients treated with this drug.&#xD;
&#xD;
      V. Determine the pharmacodynamics of this drug in these patients. VI. Correlate the presence&#xD;
      and type of B-raf, N-ras, or RET/PTC gene mutations with clinical response in patients&#xD;
      treated with this drug.&#xD;
&#xD;
      VII. Correlate the degree of Ras-MAPK signaling inhibition and vascular endothelial growth&#xD;
      factor expression with clinical response in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to diagnosis&#xD;
      (papillary thyroid cancer that is chemo-na√Øve vs all others).&#xD;
&#xD;
      Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of&#xD;
      disease progression or unacceptable toxicity. Patients achieving complete remission (CR)&#xD;
      receive 8 additional weeks of therapy beyond CR.&#xD;
&#xD;
      Patients are followed within 2-4 weeks after completion of study treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2004</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 4 weeks</time_frame>
    <description>The 95% confidence intervals should be provided.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Anaplastic Thyroid Cancer</condition>
  <condition>Insular Thyroid Cancer</condition>
  <condition>Recurrent Thyroid Cancer</condition>
  <condition>Stage III Follicular Thyroid Cancer</condition>
  <condition>Stage III Papillary Thyroid Cancer</condition>
  <condition>Stage IV Follicular Thyroid Cancer</condition>
  <condition>Stage IV Papillary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral sorafenib tosylate twice daily for up to 6 months in the absence of disease progression or unacceptable toxicity. Patients achieving CR receive 8 additional weeks of therapy beyond CR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>BAY 43-9006</other_name>
    <other_name>BAY 43-9006 Tosylate Salt</other_name>
    <other_name>BAY 54-9085</other_name>
    <other_name>Nexavar</other_name>
    <other_name>SFN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>fludeoxyglucose F 18</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>18FDG</other_name>
    <other_name>FDG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>positron emission tomography</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>FDG-PET</other_name>
    <other_name>PET</other_name>
    <other_name>PET scan</other_name>
    <other_name>tomography, emission computed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>dynamic contrast-enhanced magnetic resonance imaging</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (sorafenib tosylate)</arm_group_label>
    <other_name>DCE-MRI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Papillary thyroid cancer (stratum I)&#xD;
&#xD;
               -  Papillary, follicular, Hurthle cell, insular, or anaplastic thyroid cancer&#xD;
                  (stratum II)&#xD;
&#xD;
                    -  Mixed histology, poorly differentiated, or tall-cell variants allowed&#xD;
&#xD;
          -  Metastatic, locally advanced, or locally recurrent disease&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion &gt;= 20 mm by conventional techniques OR&#xD;
             &gt;= 10 mm by spiral CT scan&#xD;
&#xD;
               -  The following are considered non-measurable disease:&#xD;
&#xD;
                    -  Tumors in a previously irradiated area&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  Archival tumor tissue block OR material collected before study entry available&#xD;
             (stratum I)&#xD;
&#xD;
          -  Biopsy-accessible disease (stratum I)&#xD;
&#xD;
          -  Performance status - ECOG 0-1&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
          -  WBC &gt;= 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  No bleeding diathesis&#xD;
&#xD;
          -  Bilirubin =&lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT =&lt; 1.5 times ULN&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 times ULN&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to undergo 2 tumor biopsies during study participation (stratum I)&#xD;
&#xD;
          -  No history of allergic reaction attributed to compounds of similar chemical or&#xD;
             biologic composition to sorafenib&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other concurrent malignancy except nonmetastatic nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior systemic chemotherapy for thyroid cancer (stratum I)&#xD;
&#xD;
               -  Prior systemic chemotherapy used to treat a second primary cancer with curative&#xD;
                  intent allowed provided the primary cancer was treated more than 5 years before&#xD;
                  study entry&#xD;
&#xD;
          -  No more than 3 prior systemic chemotherapy regimens for thyroid cancer (stratum II)&#xD;
&#xD;
          -  More than 6 weeks since prior systemic chemotherapy (stratum II)&#xD;
&#xD;
          -  No prior external beam radiotherapy to the sole site of measurable disease (except for&#xD;
             patients with anaplastic thyroid cancer)&#xD;
&#xD;
          -  More than 6 weeks since prior external beam radiotherapy&#xD;
&#xD;
          -  More than 24 weeks since prior iodine I 131&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  No prior sorafenib&#xD;
&#xD;
          -  More than 6 weeks since prior investigational tumor-specific therapy&#xD;
&#xD;
          -  Concurrent oral or IV bisphosphonates for bony metastases allowed at the discretion of&#xD;
             the investigator&#xD;
&#xD;
          -  No other concurrent tumor-specific or investigational therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent therapeutic anticoagulation&#xD;
&#xD;
               -  Concurrent prophylactic anticoagulation (e.g., low-dose warfarin) for venous or&#xD;
                  arterial access devices allowed provided PT, INR, or PTT are normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha Shah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>November 5, 2004</study_first_submitted>
  <study_first_submitted_qc>November 5, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2004</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Cancer, Papillary</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
    <mesh_term>Adenocarcinoma, Follicular</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Fluorodeoxyglucose F18</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

